PPARγ agonists follow an unknown TRAIL in lung cancer

Cancer Biology and Therapy

Volumn 6, Issue 1, 2007, Pages 107-109

  Lipkowitz, Stanley ^a   Dennis, Phillip A ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL NAVAL MEDICAL CENTER   (United States)

Author keywords

Apoptosis; c FLIP; DR5; NSCLC; PPAR ; TRAIL

Indexed keywords

DEATH RECEPTOR 4; DEATH RECEPTOR 5; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLICE INHIBITORY PROTEIN; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHATIDYLINOSITOL 3 KINASE; PIOGLITAZONE; PROTEIN KINASE B; RETINOID X RECEPTOR; ROSIGLITAZONE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANTINEOPLASTIC AGENT; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADIPOCYTE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; COLORECTAL CANCER; DNA BINDING; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TREATMENT FAILURE; GENETIC TRANSCRIPTION; HUMAN; LIPOSARCOMA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN TARGETING; SARCOMA CELL; DRUG EFFECT; LUNG TUMOR; METABOLISM;

ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; LIGANDS; LUNG NEOPLASMS; PPAR GAMMA; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 33847107210     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.6.1.3751     Document Type: Note

References (52)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin 2006; 56:106-30.
2. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, Spitznagel EL, Piccirillo J. Changing epidemiology of small cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006; 24:4539-44.
3. Herbst RS, Bunn PA, Jr. Targeting the epidermal growth factor receptor in non-small-cell lung cancer. Clin Cancer Res 2003; 1:5813-24.
4. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 14:123-32.
5. Ashkenazi A. Targeting death and decoy receptors of the tumour necrosis factor superfamily. Nat Rev Cancer 2002; 2:420-30.
6. Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 2004; 4:333-9.
7. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3:673-82.
8. Frese S, Brunner T, Gugger M, Uduehi A, Schmid RA. Enhancement of Apo2L/TRAIL (tumor necrosis factor related apoptosis inducing ligand) induced apoptosis in non-smallcell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase 8 inhibitory protein. J Thorac Cardiovasc Surg 2002; 123:168-74.
9. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A. Control of TRAIL induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277:818-21.
10. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain containing receptor for TRAIL. Science 1997; 277:815-8.
11. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276:111-3.
12. Jeremias I, Herr I, Boehler T, Debatin KM. TRAIL/Apo 2 ligand induced apoptosis in human T cells. Eur J Immunol 1998; 28:143-52.
13. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH. Tumoricidal activity of tumor necrosis factor related apoptosis inducing ligand in vivo. Nat Med 1999; 5:157-63.
14. Kelley S, Harris LA, DeForge LE, Hebert AR, Totpal K, Zahra S, et al. The pharmacokinetics of apo2 ligand/TRAIL (APO2L/TRAIL) following a single IV bolus dose to chimpanzees. Proceedings of the 91st Annual Meeting of the AACR 2000; 41:814.
15. Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J, Fox JA. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor related apoptosis inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 2001; 299:31-8.
16. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, Hillan K, Totpal K, DeForge L, Schow P, Hooley J, Sherwood S, Pai R, Leung S, Khan L, Gliniak B, Bussiere J, Smith CA, Strom SS, Kelley S, Fox JA, Thomas D, Ashkenazi A. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001; 7:383-5.
17. Roth W, Isenmann S, Naumann U, Kugler S, Bahr M, Dichgans J, Ashkenazi A, Weller M. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem Biophys Res Commun 1999; 265:479-83.
18. Gliniak B, Le T. Tumor necrosis factor related apoptosis inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT 11. Cancer Res 1999; 59:6153-8.
19. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104:155-62.
20. Herbst RS, Mendolson DS, Ebbinghaus S, Gordon MS, O'Dwyer P, Lieberman G. A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis inducing protein in patients with advanced cancer. J Clin Oncol 2006; 24:3013.
21. Hotte SJ, Hirte HW, Chen EX, Le LH, Corey A, Maclean M. HGS ETR1, a fully human monoclonal antibody to the tumor necrosis factor related apoptosis inducing ligand death receptor 1 (TRAIL R1) in patients with advanced solid cancer: results of a phase 1 trial. J Clin Oncol 2005; 23:3052.
22. Patnaik A, Wakelee H, Mita M, Fitzgerald A, Hill M, Fox N. HGS ETR2 a fully human monoclonal antibody to TRAIL R2: results of a phase 1 trial in patients with advanced solid tumors. J Clin Oncol 2006; 24:3012.
23. Bonavida B, Ng CP, Jazirehi A, Schiller G, Mizutani Y. Selectivity of TRAIL mediated apoptosis of cancer cells and synergy with drugs: the trail to non toxic cancer therapeutics. Int J Oncol 1999; 15:793-802.
24. Cuello M, Ettenberg SA, Nau MM, Lipkowitz S. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Gynecol Oncol 2001; 81:380-90.
25. Bretz JD, Rymaszewski M, Arscott PL, Myc A, Ain KB, Thompson NW, Baker JR Jr. TRAIL death pathway expression and induction in thyroid follicular cells. J Biol Chem 1999; 274:23627-32.
26. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. Chemotherapy augments TRAIL induced apoptosis in breast cell lines. Cancer Res 1999; 59:734-41.
27. Mizutani Y, Yoshida O, Miki T, Bonavida B. Synergistic cytotoxicity and apoptosis by Apo 2 ligand and adriamycin against bladder cancer cells. Clin Cancer Res 1999; 5:2605-12.
28. Snell V, Clodi K, Zhao S, Goodwin R, Thomas EK, Morris SW, Kadin ME, Cabanillas F, Andreeff M, Younes A. Activity of TNF related apoptosis inducing ligand (TRAIL) in haematological malignancies. Br J Haematol 1997; 99:618-24.
29. Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P. Relation of TNF related apoptosis inducing ligand (TRAIL) receptor and FLICE inhibitory protein expression to TRAIL induced apoptosis of melanoma. Cancer Res 1999; 59:2747-53.
30. Gliniak B, Le T. Tumor necrosis factor related apoptosis inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT 11. Cancer Res 1999; 59:6153-8.
31. Zou W, Liu X, Yue P, Khuri FR, Sun SY. PPARgamma Ligands Enhance TRAIL induced Apoptosis through DR5 Upregulation and c FLIP Downregulation in Human Lung Cancer Cells. Cancer Biol Ther 2007; 29:6.
32. Boden G, Zhang M. Recent findings concerning thiazolidinediones in the treatment of diabetes. Expert Opin Investig Drugs 2006; 15:243-50.
33. Lehrke M, Lazar MA. The many faces of PPARgamma. Cell 2005; 16:993-9.
34. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid activated transcription factor. Cell 1994; 79:1147-56.
35. Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Fletcher CD, Brun RP, Mueller E, Altiok S, Oppenheim H, Evans RM, Spiegelman BM. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci U S A 1997; 7:237-41.
36. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S, Spiegelman BM. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1998; 1:465-70.
37. Demetri GD, Fletcher CD, Mueller E, Sarraf P, Naujoks R, Campbell N, Spiegelman BM, Singer S. Induction of solid tumor differentiation by the peroxisome proliferator activated receptor gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A 1999; 30:3951-6.
38. Debrock G, Vanhentenrijk V, Sciot R, Debiec Rychter M, Oyen R, Van Oosterom A. A phase II trial with rosiglitazone in liposarcoma patients. Br J Cancer 2003; 20:1409-12.
39. Koeffler HP. Peroxisome proliferator activated receptor gamma and cancers. Clin Cancer Res 2003; 9:1-9.
40. Li MY, Lee TW, Yim AP, Chen GG. Function of PPARgamma and its ligands in lung cancer. Crit Rev Clin Lab Sci 2006; 43:183-202.
41. Sporn MB, Suh N, Mangelsdorf DJ. Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs). Trends Mol Med 2001; 7:395-400.
42. Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, Winer EP. Use of the peroxisome proliferator activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat 2003; 79:391-7.
43. Kulke MH, Demetri GD, Sharpless NE, Ryan DP, Shivdasani R, Clark JS, Spiegelman BM, Kim H, Mayer RJ, Fuchs CS. A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy resistant metastatic colorectal cancer. Cancer J 2002; 8:395-9.
44. Smith MR, Manola J, Kaufman DS, George D, Oh WK, Mueller E, Slovin S, Spiegelman B, Small E, Kantoff PW. Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate specific antigen level after radical prostatectomy and/or radiation therapy. Cancer 2004; 101:1569-74.
45. Goke R, Goke A, Goke B, El Deiry WS, Chen Y. Pioglitazone inhibits growth of carcinoid cells and promotes TRAIL induced apoptosis by induction of p21waf1/cip1. Digestion 2001; 64:75-80.
46. Kim Y, Suh N, Sporn M, Reed JC. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL induced apoptosis. J Biol Chem 2002; 277:22320-9.
47. Lu M, Kwan T, Yu C, Chen F, Freedman B, Schafer JM, Lee EJ, Jameson JL, Jordan VC, Cryns VL. Peroxisome proliferator activated receptor gamma agonists promote TRAIL induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest. J Biol Chem 2005; 280:6742-51.
48. Nakata S, Yoshida T, Shiraishi T, Horinaka M, Kouhara J, Wakada M, Sakai T. 15 Deoxy Delta12,14 prostaglandin J(2) induces death receptor 5 expression through mRNA stabilization independently of PPARgamma and potentiates TRAIL induced apoptosis. Mol Cancer Ther 2006; 5:1827-35.
49. Schultze K, Bock B, Eckert A, Oevermann L, Ramacher D, Wiestler O, Roth W. Troglitazone sensitizes tumor cells to TRAIL induced apoptosis via down regulation of FLIP and Survivin. Apoptosis 2006; 11:1503-12.
50. Han S, Roman J. Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma dependent and PPARgamma independent signal pathways. Mol Cancer Ther 2006; 5:430-7.
51. Pacey S, Plummer RE, Attard G, Bale C, Calvert AH, Blagden S\. Phase I and pharmacokinetic study of HGS ETR2, a human monoclonal antibody to TRAIL R2, in patients with advanced solid malignancies. ASCO Annual Meeting Proceedings 2005; 23:3055.
52. Herbst RS, Mendolson DS, Ebbinghaus S, Gordon MS, O'Dwyer P, Lieberman G. A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis inducing protein in patients with advanced cancer. ASCO Annual Meeting Proceedings 2006; 24:3013.